Coronavirus Scientific Advisory Board

Naitive Technologies: Osteoporosis screening tool secures Breakthrough Designation

Retrieved on: 
Tuesday, October 10, 2023
Diagnosis, Clinical professor, Mayo Clinic, Food, BMD, Stroke, X-ray, Breast cancer, Osteoporosis, Bone fracture, Coronavirus Scientific Advisory Board, Classification, WHO, FDA, World Health Organization, Patient, Bone density, Regulation of tobacco by the U.S. Food and Drug Administration, Woman, Bone health, Face, Fracture, Physician, Medical imaging, Medical device

LONDON, Oct. 10, 2023 /PRNewswire/ -- Naitive® Technologies, a population health company, has received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for OsteoSight™, its technology for estimating bone mineral density (BMD) from routine X-rays.

Key Points: 
  • LONDON, Oct. 10, 2023 /PRNewswire/ -- Naitive® Technologies, a population health company, has received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for OsteoSight™, its technology for estimating bone mineral density (BMD) from routine X-rays.
  • [3] The Bone Health and Osteoporosis Foundation reports that fragility fractures are responsible for more hospitalizations than stroke, breast cancer, and heart attacks combined.
  • By screening patients who are having routine X-rays, we have a real opportunity to identify early bone loss and osteoporosis and prevent fractures.
  • "We are thrilled that OsteoSight has received Breakthrough Device Designation," said Dr. Will Briggs, CEO and Founder of Naitive.

Novotech Appoints Dr. Judith Ng-Cashin as Chief Medical Officer to Drive Global Medical Services

Retrieved on: 
Tuesday, October 3, 2023
Health, GSK, Anzac of the Year Award, IQVIA, Collaboration, Lead, Coronavirus Scientific Advisory Board, Infection, CMO, Quality, Syneos Health, Patient, Hematology, Rare, Therapy, DIA, AOBiome, Safety, Fine chemical, Medical device, Pharmaceutical industry, Dermatology, Stiefel

BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Novotech , the leading Asia Pacific centred biotech CRO with global execution capabilities, announced today the appointment of Dr. Judith Ng-Cashin as Chief Medical Officer (CMO).

Key Points: 
  • BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Novotech , the leading Asia Pacific centred biotech CRO with global execution capabilities, announced today the appointment of Dr. Judith Ng-Cashin as Chief Medical Officer (CMO).
  • Dr. Ng-Cashin, who brings 20 years of international pharmaceutical, biotech, and CRO experience including CMO roles, will be based in the US and lead Novotech’s global Medical Services team.
  • According to Novotech CEO, Dr. John Moller, the appointment of such a high calibre medical executive as Dr. Ng-Cashin is a significant advancement for Novotech and its biotech clients.
  • Dr. Ng-Cashin’s senior leadership roles have included Eagle Pharmaceuticals as Chief Medical Officer and Head of R&D, AOBiome Therapeutics as CMO, and Syneos Health as Chief Scientific Officer.

BPGbio Announces Promising Readout from Phase 2a Trial Evaluating BPM 31510 IV for Pancreatic Cancer

Retrieved on: 
Tuesday, October 3, 2023
Oncology, Health, Technology, Clinical Trials, Artificial Intelligence, Biotechnology, Pancreatic cancer, Survival rate, Coronavirus Scientific Advisory Board, Phosphorylation, Family, Biomarker, Advisory board, BPM, Patient, Division, Cancer, TME, Diagnosis, Rare, Death, Neurology, Tumor microenvironment, Pharmaceutical industry, Medical imaging

BPGbio, Inc. , a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that review of the Phase 2a trial in advanced, refractory pancreatic cancer patients by a Medical Advisory Board for its BPM 31510IV for Pancreatic Cancer recommends advancing the asset into a Phase 2b trial following a comprehensive analysis of data observed from a Phase 1 and completed Phase 2a clinical studies.

Key Points: 
  • BPGbio, Inc. , a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that review of the Phase 2a trial in advanced, refractory pancreatic cancer patients by a Medical Advisory Board for its BPM 31510IV for Pancreatic Cancer recommends advancing the asset into a Phase 2b trial following a comprehensive analysis of data observed from a Phase 1 and completed Phase 2a clinical studies.
  • As a result, the Advisory Board recommends the drug candidate be further assessed as a potential first-line therapy in advanced pancreatic cancer patients in the Phase 2b trial design.
  • In the Phase 2a clinical trial, BPM 31510 IV demonstrated a tolerable safety profile in advanced refractory pancreatic cancer patients with an early indication for potential clinical benefit.
  • Project Survival® has been supported by the Alliance for Families Fighting Pancreatic Cancer (AFFPC).

NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain

Retrieved on: 
Monday, October 2, 2023
Alvogen, Priority review, Patent, Partnership, Rockefeller Neuroscience Institute, Schnitzer, Nociception, File, Spinal cord, Clinical trial, Licensure, Coronavirus Scientific Advisory Board, United States patent law, NMDA, Research, CNS, Feinberg School of Medicine, Dark Enlightenment, Data collection, Pain, Thalamus, Investigational New Drug, Patient, Risk, Ketamine, DCS, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Northwestern University, Food, Pharmaceutical industry, Poultry farming, Defense, Anesthesia, Chronic pain, IND, Surgery

RADNOR, Pa., Oct. 2, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that FDA has given the company clearance to proceed with human trials to treat Chronic Pain under the Investigational New Drug (IND) application filed with the U.S. Food and Drug Administration (FDA) for the use of NRX-101.

Key Points: 
  • RADNOR, Pa., Oct. 2, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that FDA has given the company clearance to proceed with human trials to treat Chronic Pain under the Investigational New Drug (IND) application filed with the U.S. Food and Drug Administration (FDA) for the use of NRX-101.
  • "More than one in five adults in the United States suffers from chronic pain and patients lack options that do not carry the risk of addiction and opioid side effects.
  • Chronic pain is estimated to be a $72 billion industry today with the potential to grow to a $120 billion industry by 2033.
  • Dr. Apkarian is the inventor of the patent and a global expert in pain research and has important experience studying DCS in chronic pain.

Cardiost, Inc. Strengthens Scientific Advisory Board with Renowned Cardiovascular Experts, Advances Prototype Development with OEDIT Grant Support

Retrieved on: 
Friday, September 29, 2023
Medical device, University, Heart failure, Interventional cardiology, Lung transplantation, HF, Johnson & Johnson, Clinical trial, Coronavirus Scientific Advisory Board, Research, The Journal of Heart and Lung Transplantation, Biomedical engineering, Universidad, PCI, Harvard Medical School, IMACS, University of Los Andes (Colombia), CO, Journal, Wallace H. Coulter Department of Biomedical Engineering, User experience, Mount Sinai Medical Center, Publication, Biomedicine, MD, Montefiore Medical Center, Cardiology, Universidad de los Andes, Internal medicine, Fort Collins, Colorado, Journal of Cardiac Surgery, LVAD, Ventricular assist device, Hospital, MCS, Massachusetts General Hospital, CFD, Pharmaceutical industry, Heart, Patient

Cardiost is currently designing an alpha prototype of its LAUD, or Left Atrium Unloading Device, with money it received from Colorado’s OEDIT grant in early 2023.

Key Points: 
  • Cardiost is currently designing an alpha prototype of its LAUD, or Left Atrium Unloading Device, with money it received from Colorado’s OEDIT grant in early 2023.
  • The LAUD is a durable mechanical circulatory support (MCS) device to treat late-stage patients suffering from heart failure (HF).
  • Cardiost is focused on developing cardiovascular devices medical devices in the cardiovascular space.
  • “We are thrilled to add Dr. Goldstein and Dr. Moreno to our Scientific Advisory Board, both KOLs in their respective fields – MCS the former and PCI the latter.

Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer

Retrieved on: 
Thursday, September 21, 2023
KRAS, Antigen, DNA, Partnership, MD–PhD, Therapy, Blood, Doctor of Philosophy, Bacterial conjugation, Writing, MHC, Cancer, ML, Stanford University, Coronavirus Scientific Advisory Board, Microsoft, Addgene, Research, Monroe Dunaway Anderson, Harvard University, Haematopoietic system, Autoimmunity, TCR, Associate, MD Anderson Cancer Center, Chemistry, Genome, Patient, Machine learning, Melanoma, Engineering, Immune system, Autoimmune disease, Yale University, University, Physics, Biology, Entrepreneurship, Library, Synthetic biology, Prostate cancer, Pharmaceutical industry, Vaccine, Medical device, Replay, MD

This will be invaluable in helping Replay’s cell therapy product company Syena to advance novel TCR-NK therapies into the clinic.”

Key Points: 
  • This will be invaluable in helping Replay’s cell therapy product company Syena to advance novel TCR-NK therapies into the clinic.”
    “We’re thrilled to announce our first partnership with Replay and its product company Syena.
  • This partnership validates our approach of using synthesized human T cell repertoires to generate safe and effective libraries to discover antigen specific TCRs at scale,” said Elizabeth Wood, Ph.D., Founder & CEO, JURA Bio.
  • If the option is exercised, Replay and its cell therapy product company Syena will be responsible for global development and hold exclusive worldwide commercialization rights on all TCR-NK therapies resulting from the partnership.
  • Replay launched Syena, an oncology-focused product company, with The University of Texas MD Anderson Cancer Center in February 2023.

Anavo Therapeutics Strengthens Management Team

Retrieved on: 
Thursday, September 21, 2023
Oncology, Health, Other Science, General Health, Science, Pharmaceutical, Biotechnology, University of Geneva, GSK, University, Therapy, University of California, Irvine School of Physical Sciences, CSO, IGNITE, Draupnir, Coronavirus Scientific Advisory Board, Biochemistry and Cell Biology, Doctor of Philosophy, Bachelor of Science, MS, Cell biology, Patient, Serono, Drug discovery, Biology, University of York, McNulty, Merck, Pfizer, D, Pharmaceutical industry, Medical device, Pregabalin, Syntaxin, Biochemistry, Chemistry

Dr. McNulty will oversee the implementation of Anavo’s strategy from discovery into clinical development and, together with Dr. Quattropani and Anavo’s management team, the continued design of Anavo’s first- and best-in-class phosphatase-targeting allosteric modulators.

Key Points: 
  • Dr. McNulty will oversee the implementation of Anavo’s strategy from discovery into clinical development and, together with Dr. Quattropani and Anavo’s management team, the continued design of Anavo’s first- and best-in-class phosphatase-targeting allosteric modulators.
  • “We are fortunate to welcome Anna and Shaun to the Anavo team at this stage of our company’s growth,” said Birgit Zech, PhD, Chief Executive Officer of Anavo Therapeutics.
  • “Anavo’s IGNITE platform uniquely enables the rapid identification and development of therapeutics targeting phosphatases, initially thought to be undruggable targets,” said Dr. McNulty.
  • “I am excited to join the Anavo team as we continue to accelerate our proprietary portfolio of programs targeting disease-relevant phosphatases toward clinical development and to build out our next-generation approach for phosphatase targeting.”
    Anna Quattropani, PhD, joins Anavo with over 20 years of experience in medicinal chemistry and drug discovery.

JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer

Retrieved on: 
Thursday, September 21, 2023
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, KRAS, Antigen, Partnership, MD–PhD, Therapy, Blood, Doctor of Philosophy, Bacterial conjugation, MHC, Cancer, ML, Stanford University, Coronavirus Scientific Advisory Board, Microsoft, Addgene, Multimedia, Monroe Dunaway Anderson, Harvard University, Haematopoietic system, Autoimmunity, TCR, Associate, MD Anderson Cancer Center, Chemistry, Genome, Patient, Machine learning, Melanoma, University, Engineering, Immune system, Autoimmune disease, Yale University, Physics, Biology, Entrepreneurship, Library, Synthetic biology, Prostate cancer, Pharmaceutical industry, Management, Vaccine, Medical device, Replay, MD

JURA Bio , a biotechnology company developing immune-based therapeutics using machine learning and synthetic biology, announced today a research collaboration with Syena, a cell therapy product company and subsidiary of Replay, a genome writing company, to develop T cell receptor (TCR) based therapies.

Key Points: 
  • JURA Bio , a biotechnology company developing immune-based therapeutics using machine learning and synthetic biology, announced today a research collaboration with Syena, a cell therapy product company and subsidiary of Replay, a genome writing company, to develop T cell receptor (TCR) based therapies.
  • Photographer: Maki Suzuki
    “We’re thrilled to announce our first partnership with Replay and its product company Syena.
  • If the option is exercised, Replay and its cell therapy product company Syena will be responsible for global development and hold exclusive worldwide commercialization rights on all TCR-NK therapies resulting from the partnership.
  • Replay launched Syena, an oncology-focused product company, with The University of Texas MD Anderson Cancer Center in February 2023.

TOLREMO therapeutics Completes USD 39 Million Series A Financing Round with Strategic Investment from Pierre Fabre Invest

Retrieved on: 
Wednesday, September 20, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, KRAS, Gilead Sciences, SUGEN, University, Therapy, CBP, ARCH Venture Partners, Stanford University, Survival, University of California, Davis, Cancer, Pharmacokinetics, Coronavirus Scientific Advisory Board, AG, Drug resistance, Patient, EGFR, Biology, Health care, FDA, CHF, AR, Microbiology, Safety, Chair, Pharmaceutical industry, Doctor of Philosophy

TOLREMO therapeutics AG (TOLREMO) today announced that it has completed its Series A financing, bringing the total amount raised to USD 39 million (CHF 34.1 million).

Key Points: 
  • TOLREMO therapeutics AG (TOLREMO) today announced that it has completed its Series A financing, bringing the total amount raised to USD 39 million (CHF 34.1 million).
  • BioMedPartners AG led the round with participation from a new investor, Pierre Fabre Invest, as well as existing investors.
  • Stepwise, TOLREMO will then advance to evaluating TT125-802 in combination with targeted therapies such as KRAS, EGFR or AR inhibitors in specific advanced solid tumor indications.
  • In addition, Francesco Hofmann, PhD, Head of R&D for Medical Care at Pierre Fabre Laboratories, joined TOLREMO's Scientific Advisory Board.

Colossal Biosciences Joins BioRescue in Its Mission to Save the Northern White Rhino From Extinction

Retrieved on: 
Tuesday, September 19, 2023
Research, Environmental Policy, Environmental Issues, Animal Welfare, Environment, Genetics, Health Technology, Science, Biotechnology, Climate Change, Health, Public Policy, Government, Human, Colossal Biosciences, DNA, Partnership, Population study, Zoo, Ol Pejeta Conservancy, Veterinary medicine, WHO/Health Action International Project on Medicine Prices and Availability, Central African Republic, Coronavirus Scientific Advisory Board, Multimedia, Congo, Organization, Biodiversity, Northern white rhinoceros, Democratic republic, Leibniz Association, Entrepreneurship, Southern white rhinoceros, Ecosystem, Conservation, Czech, Synthetic biology, Genome, Disease, Hunting, Agriculture, Forestry, Ceratotherium, Colossal

Colossal Biosciences (“Colossal”), the world’s first de-extinction company, and BioRescue , a consortium initiating and leading the scientific rescue mission of the northern white rhino employing advanced assisted reproduction technologies and stem cell associated techniques, have teamed up to save the northern white rhino from extinction.

Key Points: 
  • Colossal Biosciences (“Colossal”), the world’s first de-extinction company, and BioRescue , a consortium initiating and leading the scientific rescue mission of the northern white rhino employing advanced assisted reproduction technologies and stem cell associated techniques, have teamed up to save the northern white rhino from extinction.
  • (Photo by Ami Vitale)
    The northern white rhino (Ceratotherium simum cottoni) is considered to be functionally extinct in the wild as a direct result of poaching.
  • “The northern white rhino is the world’s rarest large mammal and thousands of species are interlinked to its existence,” says Hildebrandt.
  • Colossal will assist the rescue mission by leveraging genome sequencing and gene editing methods to save the endangered species.